Dermatologia
Revisão | Manifestações cutâneas da gamopatia monoclonal.
18 Abr, 2022 | 15:13hCutaneous manifestations of monoclonal gammopathy – Blood Cancer Journal
M-A | Avaliação da frequência dos subtipos de rosácea em pacientes portadores desse transtorno.
14 Abr, 2022 | 17:14hAssessment of Frequency of Rosacea Subtypes in Patients With Rosacea: A Systematic Review and Meta-analysis – JAMA Dermatology (link para o resumo – $ para o texto completo)
Comentário: Study Evaluates Prevalence of 4 Major Rosacea Subtypes – HCPLive
Comentário no Twitter
In this systematic review and meta-analysis, erythematotelangiectatic and papulopustular rosacea are the most common subtypes of #rosacea based on global data. https://t.co/2lWCjrIIWP
— JAMA Dermatology (@JAMADerm) April 7, 2022
Impacto global do melanoma cutâneo em 2020 e projeções para 2040.
1 Abr, 2022 | 12:14hGlobal Burden of Cutaneous Melanoma in 2020 and Projections to 2040 – JAMA Dermatology (gratuito por tempo limitado)
Editorial: Melanoma Epidemiology—Pivoting to Low- and Middle-Income Countries (gratuito por tempo limitado)
Comentário: Global Burden of Melanoma Considerable, Set to Rise by 2040 – HealthDay
Estudo randomizado | Introdução de adalimumabe vs. escalonamento de dose de metotrexato em pacientes com artrite psoriática com controle inadequado.
29 Mar, 2022 | 14:31hComparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study – The Lancet Rheumatology (link para o resumo – $ para o texto completo)
Comentário:
Comentário no Twitter
NEW RESEARCH—A randomised, open-label, phase 4 trial supports the addition of #adalimumab over escalating in patients with #PsoriaticArthritis not reaching minimal disease activity after an initial methotrexate course https://t.co/LUpzAw71lD #LancetRheumatology pic.twitter.com/ouqTyITlxC
— The Lancet Rheumatology (@TheLancetRheum) February 28, 2022
Estudo randomizado | Dois estudos de fase 3 sobre baricitinibe para alopecia areata.
29 Mar, 2022 | 14:01hTwo Phase 3 Trials of Baricitinib for Alopecia Areata – New England Journal of Medicine
Comentário no Twitter
Alopecia areata is a distressing disorder of hair loss that is mediated partly by cytokines dependent on Janus kinases. The JAK1 and JAK2 inhibitor baricitinib reduced the extent of hair loss in two randomized trials over a period of 36 weeks. #AAD2022 https://t.co/oKKzGF7Q5S pic.twitter.com/gsgWJ1asZN
— NEJM (@NEJM) March 26, 2022
Estudo randomizado | Debridamento de queimaduras hidrocirúrgico vs. convencional.
29 Mar, 2022 | 13:47h
Comentário no Twitter
In the April issue of BJS: Hydrosurgical and conventional debridement of burns: randomized clinical trial https://t.co/XoN6w3xkRU @AmyLightnerMD @bplwijn @des_winter @ksoreide @MalinASund @evanscolorectal @nfmkok @robhinchliffe1 @young_bjs pic.twitter.com/YSkczkqnTU
— BJS (@BJSurgery) March 25, 2022
Revisão | Achados em exames de imagem de tumores cutâneos malignos: correlação patológica.
25 Mar, 2022 | 15:37hEstimativa do diagnóstico excessivo (overdiagnosis) de melanoma usando tendências entre pacientes negros e brancos nos EUA.
25 Mar, 2022 | 14:52hEstimating Overdiagnosis of Melanoma Using Trends Among Black and White Patients in the US – JAMA Dermatology (link para o resumo – $ para o texto completo)
Comentário: Deadly form of skin cancer ‘overdiagnosed’ in some patients, study finds – UPI
Comentário do autor no Twitter (fio – clique para saber mais)
The wildest thing about this paper is we wrote it in 2017, then shelved it because of the initial push back in peer review. This experience taught me A LOT about when colleagues are ready to accept ideas that challenge their thinking. 🧵
1/9 https://t.co/hXDURXkwju— Ade Adamson, MD MPP (@AdeAdamson) March 20, 2022
Diretrizes europeias sobre diagnóstico e tratamento de penfigoide de membranas mucosas.
24 Mar, 2022 | 12:13hEstudo randomizado | Inibição da pré-calicreína no angioedema hereditário.
24 Mar, 2022 | 12:10hInhibition of Prekallikrein for Hereditary Angioedema – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Conteúdos relacionados:
Phase 2 RCT: Prophylactic use of garadacimab in patients with hereditary angioedema.
Evaluation and Management of Angioedema in the Emergency Department